

Jiake Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6396104/publications.pdf>

Version: 2024-02-01

153
papers

7,719
citations

71102

41
h-index

64796

79
g-index

155
all docs

155
docs citations

155
times ranked

9132
citing authors

#	ARTICLE	IF	CITATIONS
1	The molecular structure and role of LECT2 or CHM4 in arthritis, cancer, and other diseases. <i>Journal of Cellular Physiology</i> , 2022, 237, 480-488.	4.1	9
2	Roburic acid attenuates osteoclastogenesis and bone resorption by targeting RANKL-induced intracellular signaling pathways. <i>Journal of Cellular Physiology</i> , 2022, 237, 1790-1803.	4.1	8
3	Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 848152.	3.5	3
4	The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 823354.	3.7	12
5	CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis via Modulating RANKL and ROS Signaling Pathways. <i>Frontiers in Pharmacology</i> , 2022, 13, 829862.	3.5	7
6	Single-cell RNA-seq identification of four differentially expressed survival-related genes by a TARGET: Osteosarcoma database analysis. <i>Experimental Biology and Medicine</i> , 2022, 247, 921-930.	2.4	5
7	Versatile subtypes of pericytes and their roles in spinal cord injury repair, bone development and repair. <i>Bone Research</i> , 2022, 10, 30.	11.4	29
8	Chrysin Protects Against Titanium Particle-Induced Osteolysis by Attenuating Osteoclast Formation and Function by Inhibiting NF- κ B and MAPK Signaling. <i>Frontiers in Pharmacology</i> , 2022, 13, 793087.	3.5	10
9	Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway. <i>European Journal of Pharmacology</i> , 2022, 923, 174908.	3.5	5
10	Molecular structure, expression, and the emerging role of Siglec15 in skeletal biology and cancer. <i>Journal of Cellular Physiology</i> , 2022, 237, 1711-1719.	4.1	6
11	Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma. <i>Experimental Biology and Medicine</i> , 2022, 247, 1214-1227.	2.4	14
12	Molecular structure and function of microfibrillar-associated proteins in skeletal and metabolic disorders and cancers. <i>Journal of Cellular Physiology</i> , 2021, 236, 41-48.	4.1	30
13	The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapies. <i>Journal of Cellular Physiology</i> , 2021, 236, 1606-1615.	4.1	16
14	Carnosol suppresses RANKL-induced osteoclastogenesis and attenuates titanium particles-induced osteolysis. <i>Journal of Cellular Physiology</i> , 2021, 236, 1950-1966.	4.1	15
15	The molecular structure and function of sorting nexin 10 in skeletal disorders, cancers, and other pathological conditions. <i>Journal of Cellular Physiology</i> , 2021, 236, 4207-4215.	4.1	6
16	Circular \langle sc \rangle RNAs \langle /sc \rangle in childhood-related diseases and cancers: A review. <i>Cell Biochemistry and Function</i> , 2021, 39, 458-467.	2.9	5
17	A missense mutation sheds light on a novel structure-function relationship of RANKL. <i>Journal of Cellular Physiology</i> , 2021, 236, 2800-2816.	4.1	15
18	Inhibitory effects of biochanin A on titanium particle-induced osteoclast activation and inflammatory bone resorption via NF- κ B and MAPK pathways. <i>Journal of Cellular Physiology</i> , 2021, 236, 1432-1444.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Molecular structure, gene expression and functional role of <i>WFDC1</i> in angiogenesis and cancer. <i>Cell Biochemistry and Function</i> , 2021, 39, 588-595.	2.9	7
20	Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. <i>Journal of Cellular Physiology</i> , 2021, 236, 6090-6100.	4.1	38
21	AAV2-mediated and hypoxia response element-directed expression of bFGF in neural stem cells showed therapeutic effects on spinal cord injury in rats. <i>Cell Death and Disease</i> , 2021, 12, 274.	6.3	32
22	New physiological insights into the phenomena of deer antler: A unique model for skeletal tissue regeneration. <i>Journal of Orthopaedic Translation</i> , 2021, 27, 57-66.	3.9	16
23	12 Survival-related differentially expressed genes based on the TARGET-osteosarcoma database. <i>Experimental Biology and Medicine</i> , 2021, 246, 2072-2081.	2.4	19
24	The effects of biophysical stimulation on osteogenic differentiation and the mechanisms from <i>ncRNAs</i> . <i>Cell Biochemistry and Function</i> , 2021, 39, 727-739.	2.9	6
25	Biological insights into the rapid tissue regeneration of freshwater crayfish and crustaceans. <i>Cell Biochemistry and Function</i> , 2021, 39, 740-753.	2.9	3
26	Notopterol Attenuates Estrogen Deficiency-Induced Osteoporosis via Repressing RANKL Signaling and Reactive Oxygen Species. <i>Frontiers in Pharmacology</i> , 2021, 12, 664836.	3.5	18
27	Patchouli Alcohol Modulates the Pregnancy X Receptor/Toll-like Receptor 4/Nuclear Factor Kappa B Axis to Suppress Osteoclastogenesis. <i>Frontiers in Pharmacology</i> , 2021, 12, 684976.	3.5	4
28	Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 709210.	2.8	54
29	Current research progress in targeted anti-angiogenesis therapy for osteosarcoma. <i>Cell Proliferation</i> , 2021, 54, e13102.	5.3	39
30	Upregulation of 15 Antisense Long Non-Coding RNAs in Osteosarcoma. <i>Genes</i> , 2021, 12, 1132.	2.4	26
31	Morin attenuates osteoclast formation and function by suppressing the <i>NF-κB</i> , <i>MAPK</i> and calcium signalling pathways. <i>Phytotherapy Research</i> , 2021, 35, 5694-5707.	5.8	6
32	Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity. <i>Frontiers in Pharmacology</i> , 2021, 12, 645140.	3.5	15
33	Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. <i>Biochemical Pharmacology</i> , 2021, 193, 114761.	4.4	42
34	STAT3 and its targeting inhibitors in osteosarcoma. <i>Cell Proliferation</i> , 2021, 54, e12974.	5.3	82
35	12-Deoxyphorbol 13-acetate inhibits RANKL-induced osteoclastogenesis via the attenuation of MAPK signaling and NFATc1 activation. <i>International Immunopharmacology</i> , 2021, 101, 108177.	3.8	4
36	The SQSTM1/p62 UBA domain regulates Ajuba localisation, degradation and NF- κ B signalling function. <i>PLoS ONE</i> , 2021, 16, e0259556.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF- κ B, Calcium, and NFATc1 Pathways. <i>Frontiers in Pharmacology</i> , 2021, 12, 810322.	3.5	12
38	m6A Methylation Regulates Osteoblastic Differentiation and Bone Remodeling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 783322.	3.7	43
39	The emerging roles of hnRNPK. <i>Journal of Cellular Physiology</i> , 2020, 235, 1995-2008.	4.1	85
40	Molecular structure and the role of high-temperature requirement protein 1 in skeletal disorders and cancers. <i>Cell Proliferation</i> , 2020, 53, e12746.	5.3	14
41	Donkey genomes provide new insights into domestication and selection for coat color. <i>Nature Communications</i> , 2020, 11, 6014.	12.8	63
42	Alternative splicing of leptin receptor overlapping transcript in osteosarcoma. <i>Experimental Biology and Medicine</i> , 2020, 245, 1437-1443.	2.4	10
43	Maackiain dampens osteoclastogenesis via attenuating RANKL-stimulated NF- κ B signalling pathway and NFATc1 activity. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12308-12317.	3.6	15
44	Endothelial cells produce angiocrine factors to regulate bone and cartilage via versatile mechanisms. <i>Theranostics</i> , 2020, 10, 5957-5965.	10.0	55
45	Fumitremorgin C Attenuates Osteoclast Formation and Function via Suppressing RANKL-Induced Signaling Pathways. <i>Frontiers in Pharmacology</i> , 2020, 11, 238.	3.5	8
46	Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways. <i>Frontiers in Pharmacology</i> , 2020, 11, 1025.	3.5	13
47	The role of glial cell line-derived neurotrophic factor family member artemin in neurological disorders and cancers. <i>Cell Proliferation</i> , 2020, 53, e12860.	5.3	20
48	Conditional Knockout of PKC- ζ in Osteoclasts Favors Bone Mass Accrual in Males Due to Decreased Osteoclast Function. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 450.	3.7	6
49	Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3303-3313.	3.6	15
50	Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption. <i>Journal of Cellular Physiology</i> , 2020, 235, 5951-5961.	4.1	19
51	Hymenialdisine: A Marine Natural Product That Acts on Both Osteoblasts and Osteoclasts and Prevents Estrogen-Dependent Bone Loss in Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1582-1596.	2.8	34
52	Steroid-induced osteonecrosis of the femoral head reveals enhanced reactive oxygen species and hyperactive osteoclasts. <i>International Journal of Biological Sciences</i> , 2020, 16, 1888-1900.	6.4	58
53	Molecular structure, expression, and functional role of Clec11a in skeletal biology and cancers. <i>Journal of Cellular Physiology</i> , 2020, 235, 6357-6365.	4.1	19
54	The repair and autophagy mechanisms of hypoxia-regulated bFGF-modified primary embryonic neural stem cells in spinal cord injury. <i>Stem Cells Translational Medicine</i> , 2020, 9, 603-619.	3.3	22

#	ARTICLE	IF	CITATIONS
55	Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. <i>Pharmacological Research</i> , 2020, 159, 104944.	7.1	32
56	Cytoplasmic PCNA is located in the actin belt and involved in osteoclast differentiation. <i>Aging</i> , 2020, 12, 13297-13317.	3.1	10
57	Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption. <i>Journal of Cellular Physiology</i> , 2019, 234, 789-801.	4.1	11
58	MiR-214 is an important regulator of the musculoskeletal metabolism and disease. <i>Journal of Cellular Physiology</i> , 2019, 234, 231-245.	4.1	49
59	Asiaticoside, a component of <i>Centella asiatica</i> attenuates RANKL-induced osteoclastogenesis via NFATc1 and NF- κ B signaling pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 4267-4276.	4.1	28
60	Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. <i>Theranostics</i> , 2019, 9, 4648-4662.	10.0	141
61	Emerging Trend in the Pharmacotherapy of Osteoarthritis. <i>Frontiers in Endocrinology</i> , 2019, 10, 431.	3.5	68
62	Chondromodulin-1 in health, osteoarthritis, cancer, and heart disease. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4493-4502.	5.4	20
63	Connecting Versatile lncRNAs with Heterogeneous Nuclear Ribonucleoprotein K and Pathogenic Disorders. <i>Trends in Biochemical Sciences</i> , 2019, 44, 733-736.	7.5	14
64	MiR-214 Attenuates the Osteogenic Effects of Mechanical Loading on Osteoblasts. <i>International Journal of Sports Medicine</i> , 2019, 40, 931-940.	1.7	18
65	Asperpyrone A attenuates RANKL-induced osteoclast formation through inhibiting NFATc1, Ca ²⁺ signalling and oxidative stress. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8269-8279.	3.6	13
66	Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8355-8368.	3.6	16
67	The Effect of Exercise on the Prevention of Osteoporosis and Bone Angiogenesis. <i>BioMed Research International</i> , 2019, 2019, 1-8.	1.9	75
68	Protein Cyt11: its role in chondrogenesis, cartilage homeostasis, and disease. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3515-3523.	5.4	22
69	Osthole inhibits osteoclasts formation and bone resorption by regulating NF- κ B signaling and NFATc1 activations stimulated by RANKL. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16052-16061.	2.6	21
70	Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species. <i>Theranostics</i> , 2019, 9, 1634-1650.	10.0	165
71	Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF- κ B and MAPK pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 17600-17611.	4.1	23
72	Discovery of new inhibitors against both NF- κ B and osteoclastogenesis from in-house library with β -unsaturated-enone fragment. <i>Bioorganic Chemistry</i> , 2019, 87, 638-646.	4.1	3

#	ARTICLE	IF	CITATIONS
73	Dehydrocostus lactone (DHC) suppresses estrogen deficiency-induced osteoporosis. <i>Biochemical Pharmacology</i> , 2019, 163, 279-289.	4.4	12
74	Cumambrin A prevents OVX-induced osteoporosis via the inhibition of osteoclastogenesis, bone resorption, and RANKL signaling pathways. <i>FASEB Journal</i> , 2019, 33, 6726-6735.	0.5	11
75	Tiliroside is a new potential therapeutic drug for osteoporosis in mice. <i>Journal of Cellular Physiology</i> , 2019, 234, 16263-16274.	4.1	6
76	Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 17812-17823.	4.1	25
77	Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1344.	3.5	87
78	Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation. <i>RSC Advances</i> , 2019, 9, 38438-38446.	3.6	10
79	Cepharanthine suppresses osteoclast formation by modulating the nuclear factor- κ B and nuclear factor of activated T-cell signaling pathways. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1990-1996.	2.6	10
80	Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 522-534.	3.6	24
81	Salidroside promotes rat spinal cord injury recovery by inhibiting inflammatory cytokine expression and NF- κ B and MAPK signaling pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 14259-14269.	4.1	39
82	Vaccarin prevents titanium particle-induced osteolysis and inhibits RANKL-induced osteoclastogenesis by blocking NF- κ B and MAPK signaling pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 13832-13842.	4.1	15
83	Pectolarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling. <i>Journal of Cellular Physiology</i> , 2019, 234, 13959-13968.	4.1	12
84	Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 380-394.	3.6	34
85	Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation. <i>Journal of Cellular Physiology</i> , 2019, 234, 6477-6488.	4.1	17
86	Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo. <i>Journal of Cellular Physiology</i> , 2019, 234, 11951-11959.	4.1	6
87	Diosmetin inhibits osteoclast formation and differentiation and prevents LPS-induced osteolysis in mice. <i>Journal of Cellular Physiology</i> , 2019, 234, 12701-12713.	4.1	18
88	Cajanin stilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 11792-11804.	4.1	14
89	Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 1587.	3.5	21
90	Poria cocos polysaccharide attenuates RANKL-induced osteoclastogenesis by suppressing NFATc1 activity and phosphorylation of ERK and STAT3. <i>Archives of Biochemistry and Biophysics</i> , 2018, 647, 76-83.	3.0	23

#	ARTICLE	IF	CITATIONS
91	Synthesis of Janus Au nanorods/polydivinylbenzene hybrid nanoparticles for chemo-photothermal therapy. <i>Journal of Materials Chemistry B</i> , 2018, 6, 2481-2488.	5.8	22
92	<i>Achyranthes bidentata</i> polysaccharide suppresses osteoclastogenesis and bone resorption via inhibiting RANKL signaling. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4826-4835.	2.6	25
93	Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. <i>Bone Research</i> , 2018, 6, 15.	11.4	947
94	Carnosic acid inhibits inflammation response and joint destruction on osteoclasts, fibroblast-like synoviocytes, and collagen-induced arthritis rats. <i>Journal of Cellular Physiology</i> , 2018, 233, 6291-6303.	4.1	38
95	Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo. <i>Journal of Cellular Physiology</i> , 2018, 233, 476-485.	4.1	44
96	The emerging role of NPNT in tissue injury repair and bone homeostasis. <i>Journal of Cellular Physiology</i> , 2018, 233, 1887-1894.	4.1	19
97	Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. <i>Journal of Cellular Physiology</i> , 2018, 233, 1723-1735.	4.1	35
98	The emerging role of Hippo signaling pathway in regulating osteoclast formation. <i>Journal of Cellular Physiology</i> , 2018, 233, 4606-4617.	4.1	56
99	Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. <i>Journal of Cellular Physiology</i> , 2018, 233, 2502-2512.	4.1	48
100	Coupling factors and exosomal packaging microRNA involved in the regulation of bone remodelling. <i>Biological Reviews</i> , 2018, 93, 469-480.	10.4	76
101	TNF- α inhibits SATB2 expression and osteoblast differentiation through NF- κ B and MAPK pathways. <i>Oncotarget</i> , 2018, 9, 4833-4850.	1.8	31
102	<i>Cistanche deserticola</i> polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production. <i>Journal of Cellular Physiology</i> , 2018, 233, 9674-9684.	4.1	32
103	Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 644-656.	1.6	9
104	Light-Triggered Biomimetic Nanoerythrocyte for Tumor-Targeted Lung Metastatic Combination Therapy of Malignant Melanoma. <i>Small</i> , 2018, 14, e1801754.	10.0	89
105	Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling. <i>Journal of Cellular Physiology</i> , 2018, 233, 8971-8983.	4.1	9
106	EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. <i>Journal of Cellular Physiology</i> , 2018, 233, 8526-8537.	4.1	46
107	MicroRNAs as Potential Targets for Treatment of Osteoclast-Related Diseases. <i>Current Drug Targets</i> , 2018, 19, 422-431.	2.1	9
108	The Emerging Role of MORC Family Proteins in Cancer Development and Bone Homeostasis. <i>Journal of Cellular Physiology</i> , 2017, 232, 928-934.	4.1	35

#	ARTICLE	IF	CITATIONS
109	Mechanical Stress Regulates Bone Metabolism Through MicroRNAs. <i>Journal of Cellular Physiology</i> , 2017, 232, 1239-1245.	4.1	57
110	Massage Alleviates Delayed Onset Muscle Soreness after Strenuous Exercise: A Systematic Review and Meta-Analysis. <i>Frontiers in Physiology</i> , 2017, 8, 747.	2.8	53
111	Bajjiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF- κ B and NFAT. <i>International Journal of Molecular Sciences</i> , 2017, 18, 203.	4.1	25
112	Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis. <i>Current Drug Targets</i> , 2017, 18, 1051-1068.	2.1	101
113	Natural Compounds for the Treatment of Psoriatic Arthritis: A Proposal Based on Multi-Targeted Osteoclastic Regulation and on a Preclinical Study. <i>JMIR Research Protocols</i> , 2017, 6, e132.	1.0	10
114	Treadmill running exercise prevents senile osteoporosis and upregulates the Wnt signaling pathway in SAMP6 mice. <i>Oncotarget</i> , 2016, 7, 71072-71086.	1.8	22
115	Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling Pathways. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 964-974.	2.8	88
116	Cytoplasmic hnRNPk interacts with GSK3 β and is essential for the osteoclast differentiation. <i>Scientific Reports</i> , 2016, 5, 17732.	3.3	35
117	Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiation. <i>Scientific Reports</i> , 2016, 6, 36662.	3.3	24
118	NPNT is Expressed by Osteoblasts and Mediates Angiogenesis via the Activation of Extracellular Signal-regulated Kinase. <i>Scientific Reports</i> , 2016, 6, 36210.	3.3	24
119	Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. <i>Nature Communications</i> , 2016, 7, 10872.	12.8	424
120	Current research on pharmacologic and regenerative therapies for osteoarthritis. <i>Bone Research</i> , 2016, 4, 15040.	11.4	355
121	Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity. <i>Journal of Cellular Physiology</i> , 2016, 231, 1983-1993.	4.1	28
122	Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1211-1218.	0.9	29
123	Protein kinase C delta null mice exhibit structural alterations in articular surface, intra-articular and subchondral compartments. <i>Arthritis Research and Therapy</i> , 2015, 17, 210.	3.5	13
124	Natural Germacrene Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF- κ B Activation, and β Casein Degradation. <i>International Journal of Molecular Sciences</i> , 2015, 16, 26599-26607.	4.1	13
125	Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF- κ B and NFAT Pathways. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27087-27096.	4.1	29
126	Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27470-27481.	4.1	16

#	ARTICLE	IF	CITATIONS
127	Protein Kinase C Inhibitor, GF109203X Attenuates Osteoclastogenesis, Bone Resorption and RANKL-Induced NF- κ B and NFAT Activity. <i>Journal of Cellular Physiology</i> , 2015, 230, 1235-1242.	4.1	22
128	Choline Kinase $\hat{1}^2$ Mutant Mice Exhibit Reduced Phosphocholine, Elevated Osteoclast Activity, and Low Bone Mass. <i>Journal of Biological Chemistry</i> , 2015, 290, 1729-1742.	3.4	24
129	MAGED1 Is a Negative Regulator of Bone Remodeling in Mice. <i>American Journal of Pathology</i> , 2015, 185, 2653-2667.	3.8	16
130	microRNA-103a Functions as a Mechanosensitive microRNA to Inhibit Bone Formation Through Targeting Runx2. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 330-345.	2.8	142
131	Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF- κ B activation and titanium particle-induced osteolysis in a mouse model. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 346-353.	3.2	37
132	EGFL7 Is Expressed in Bone Microenvironment and Promotes Angiogenesis via ERK, STAT3, and Integrin Signaling Cascades. <i>Journal of Cellular Physiology</i> , 2015, 230, 82-94.	4.1	40
133	HtrA1 is upregulated during RANKL-induced osteoclastogenesis, and negatively regulates osteoblast differentiation and BMP2-induced Smad1/5/8, ERK and p38 phosphorylation. <i>FEBS Letters</i> , 2014, 588, 143-150.	2.8	30
134	SC-514, a selective inhibitor of IKK $\hat{1}^2$ attenuates RANKL-induced osteoclastogenesis and NF- κ B activation. <i>Biochemical Pharmacology</i> , 2013, 86, 1775-1783.	4.4	42
135	Angiogenic factors in bone local environment. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 297-310.	7.2	208
136	HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. <i>Biochemical Journal</i> , 2013, 451, 235-244.	3.7	60
137	Loss of Protein Kinase C- $\hat{1}$ Protects against LPS-Induced Osteolysis Owing to an Intrinsic Defect in Osteoclastic Bone Resorption. <i>PLoS ONE</i> , 2013, 8, e70815.	2.5	23
138	An overview of the regulation of bone remodelling at the cellular level. <i>Clinical Biochemistry</i> , 2012, 45, 863-873.	1.9	408
139	Membrane-bound receptor activator of NF- κ B ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors. <i>Biochemical and Biophysical Research Communications</i> , 2012, 422, 48-53.	2.1	28
140	Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF- κ B and ERK activation. <i>FEBS Letters</i> , 2011, 585, 2755-2762.	2.8	89
141	Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF- κ B and ERK. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 89-97.	2.6	69
142	EGFL6 Promotes Endothelial Cell Migration and Angiogenesis through the Activation of Extracellular Signal-regulated Kinase. <i>Journal of Biological Chemistry</i> , 2011, 286, 22035-22046.	3.4	95
143	Myocyte Enhancer Factor 2 and Microphthalmia-associated Transcription Factor Cooperate with NFATc1 to Transactivate the V-ATPase d2 Promoter during RANKL-induced Osteoclastogenesis. <i>Journal of Biological Chemistry</i> , 2009, 284, 14667-14676.	3.4	87
144	Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation. <i>Molecular Endocrinology</i> , 2009, 23, 35-46.	3.7	18

#	ARTICLE	IF	CITATIONS
145	Proteasome inhibitors impair RANKL-induced NF- κ B activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and I κ B β signaling cascades. <i>Journal of Cellular Physiology</i> , 2009, 220, 450-459.	4.1	61
146	NF- κ B modulators in osteolytic bone diseases. <i>Cytokine and Growth Factor Reviews</i> , 2009, 20, 7-17.	7.2	205
147	Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL). <i>Journal of Cellular Physiology</i> , 2007, 212, 787-795.	4.1	65
148	p62 Ubiquitin Binding-Associated Domain Mediated the Receptor Activator of Nuclear Factor- κ B Ligand-Induced Osteoclast Formation. <i>American Journal of Pathology</i> , 2006, 169, 503-514.	3.8	70
149	Thapsigargin Modulates Osteoclastogenesis Through the Regulation of RANKL-Induced Signaling Pathways and Reactive Oxygen Species Production. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1462-1471.	2.8	77
150	Sesquiterpene Lactone Parthenolide Blocks Lipopolysaccharide-Induced Osteolysis Through the Suppression of NF- κ B Activity. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1905-1916.	2.8	81
151	12-O-tetradecanoylphorbol-13-acetate (TPA) Inhibits Osteoclastogenesis by Suppressing RANKL-Induced NF- κ B Activation. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2159-2168.	2.8	132
152	Cloning, Sequencing, and Functional Characterization of the Rat Homologue of Receptor Activator of NF- κ B Ligand. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 2178-2186.	2.8	152
153	Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF- κ B in Giant Cell Tumor of Bone. <i>American Journal of Pathology</i> , 2000, 156, 761-767.	3.8	260